CY2607B2 - Συνεργιστικος συνδυασμος αναστολεων pde και αγωνιστων αδενυλικης κυκλασης ή αγωνιστων γουανυλικης κυκλασης - Google Patents

Συνεργιστικος συνδυασμος αναστολεων pde και αγωνιστων αδενυλικης κυκλασης ή αγωνιστων γουανυλικης κυκλασης

Info

Publication number
CY2607B2
CY2607B2 CY0900008A CY0900008A CY2607B2 CY 2607 B2 CY2607 B2 CY 2607B2 CY 0900008 A CY0900008 A CY 0900008A CY 0900008 A CY0900008 A CY 0900008A CY 2607 B2 CY2607 B2 CY 2607B2
Authority
CY
Cyprus
Prior art keywords
agonists
guanylcyclyse
adenylate cyclase
pde inhibitors
synergistic combination
Prior art date
Application number
CY0900008A
Other languages
English (en)
Inventor
Rolf Beume
Dieter Flockerzi
Klaus-Dieter Beller
Friedrich Grimminger
Norbert Suttorp
Christian Schudt
Original Assignee
Nycomed Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Gmbh filed Critical Nycomed Gmbh
Publication of CY2607B2 publication Critical patent/CY2607B2/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Η εφεύρεση αφορά την συνδυασμένη εφαρμογή αναστολέων PDE και αγωνιστών αδενυλικής κυκλάσης ή αγωνιστών γουανυλικής κυκλάσης για τη θεραπεία ορισμένων καταστάσεων ασθενειών, όπως για παράδειγμα της πνευμονικής υπερτονίας.
CY0900008A 1997-02-28 2009-06-11 Συνεργιστικος συνδυασμος αναστολεων pde και αγωνιστων αδενυλικης κυκλασης ή αγωνιστων γουανυλικης κυκλασης CY2607B2 (el)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19708049 1997-02-28

Publications (1)

Publication Number Publication Date
CY2607B2 true CY2607B2 (el) 2010-04-28

Family

ID=7821764

Family Applications (1)

Application Number Title Priority Date Filing Date
CY0900008A CY2607B2 (el) 1997-02-28 2009-06-11 Συνεργιστικος συνδυασμος αναστολεων pde και αγωνιστων αδενυλικης κυκλασης ή αγωνιστων γουανυλικης κυκλασης

Country Status (12)

Country Link
US (1) US6333354B1 (el)
EP (1) EP0975347B1 (el)
JP (2) JP2001513097A (el)
AT (1) ATE386531T1 (el)
AU (1) AU6823098A (el)
CY (1) CY2607B2 (el)
DE (1) DE59814173D1 (el)
DK (1) DK0975347T3 (el)
ES (1) ES2302350T3 (el)
PT (1) PT975347E (el)
SI (1) SI0975347T1 (el)
WO (1) WO1998037894A1 (el)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001516765A (ja) * 1997-09-12 2001-10-02 ヴォルフ ゲオルグ フォースマン 真性糖尿病及び肥満の治療のための組成物
PL346271A1 (en) * 1998-08-26 2002-01-28 Smithkline Beecham Corp Therapies for treating pulmonary diseases
IL137429A0 (en) * 1999-07-28 2001-07-24 Pfizer Prod Inc Methods and compsitions for treating diseases and conditions of the eye
JP2003506394A (ja) * 1999-08-10 2003-02-18 ボード オブ リージェンツ， ザ ユニバーシティ オブ テキサス システム 視力の保持を容易にするために視神経、脈絡膜、および網膜の血流を増大させるための方法
MXPA02001830A (es) * 1999-08-21 2002-08-12 Byk Gulden Lomberg Chem Fab Combinacion sinergica de inhibidores de pde y agonista de beta 2 adrenoceptor.
TW200400821A (en) * 1999-11-02 2004-01-16 Pfizer Pharmaceutical composition (II) useful for treating or preventing pulmonary hypertension in a patient
BR0111440A (pt) 2000-06-05 2003-06-03 Altana Pharma Ag Compostos eficazes como agonistas do (beta)2-adrenorreceptor bem como inibidores de pde4
AU2000270300A1 (en) * 2000-09-13 2002-03-26 Isis Innovation Limited Use of phosphodiesterase inhibitors for the treatment of anorectal disorders
DE10061137B4 (de) * 2000-12-07 2016-10-06 Takeda Gmbh Neue pharmazeutische Zubereitung
JP2005509621A (ja) * 2001-10-17 2005-04-14 ユニバーシティ オブ ウェールズ カレッジ オブ メディスン ギャップ結合ならびにｅｄｈｆ
WO2003051346A2 (en) * 2001-12-17 2003-06-26 Altana Pharma Ag Use of selective pde5 inhibitors for treating partial and global respiratory failure
US7276529B2 (en) * 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US7208516B2 (en) * 2002-03-20 2007-04-24 Celgene Corporation Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
WO2003087333A2 (en) * 2002-04-12 2003-10-23 Celgene Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
JP2005536189A (ja) * 2002-04-12 2005-12-02 セルジーン・コーポレーション 血管新生のモジュレーターの同定方法、それにより見出された化合物および該化合物を使用する治療方法
WO2003097050A2 (en) * 2002-05-16 2003-11-27 Pharmacia Corporation A selective inos inhibitor and a pde inhibitor in combination for the treatment of respiratory diseases
US20040077639A1 (en) * 2002-05-16 2004-04-22 Manning Pamela T. Methods for the treatment of respiratory diseases and conditions using a selective iNOS inhibitor
MXPA05002146A (es) * 2002-09-16 2005-05-23 Alcon Mfg Ltd Uso de inhibidores de pde iv para tratar la angiogenesis.
ES2309357T3 (es) * 2002-11-27 2008-12-16 Nycomed Gmbh Nueva combinacion sinergica que comprende roflumilast y formoterol.
BR0316475A (pt) * 2002-11-27 2005-10-11 Altana Pharma Ag Combinação sinergìstica que compreende roflumilast e (r,r)-formoterol
WO2004067006A1 (en) * 2003-01-27 2004-08-12 Pharmacia Corporation Combination of a pde iv inhibitor and a tnf-alpha antagonist
SG168407A1 (en) 2003-01-28 2011-02-28 Ironwood Pharmaceuticals Inc Methods and compositions for the treatment of gastrointestinal disorders
MXPA05011225A (es) * 2003-04-18 2005-12-14 Pharmacia & Upjohn Co Llc Politerapias.
WO2006111495A1 (en) 2005-04-19 2006-10-26 Nycomed Gmbh Roflumilast for the treatment of pulmonary hypertension
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
WO2007025177A2 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2377530A3 (en) 2005-10-21 2012-06-20 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2377531A2 (en) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenesis by modulating angiotensin
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
MX2009002496A (es) * 2006-09-08 2009-07-10 Braincells Inc Combinaciones que contienen un derivado de 4-acilaminopiridina.
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
CA2718412A1 (en) * 2008-03-24 2009-10-01 Celgene Corporation Treatment of psoriasis or psoriatic arthritis using cyclopropyl-n-{2-{(1s)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
WO2010019450A2 (en) * 2008-08-09 2010-02-18 Nyles Bauer Synergizing active compounds for treating inflammation and other conditions
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
JP5502106B2 (ja) 2008-12-31 2014-05-28 アーデリクス，インコーポレーテッド 体液貯留または塩分過負荷と関連する障害および消化管障害の治療におけるｎｈｅ媒介性アンチポートを阻害するための組成物および方法
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US11464781B2 (en) 2009-02-25 2022-10-11 Intra-Cellular Therapies, Inc. PDE1 inhibitors for ophthalmic disorders
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
EP2804603A1 (en) 2012-01-10 2014-11-26 President and Fellows of Harvard College Beta-cell replication promoting compounds and methods of their use
CA2880338A1 (en) 2012-08-21 2014-02-27 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
CA2909169A1 (en) 2013-04-12 2014-10-16 Ardelyx, Inc. Nhe3-binding compounds and methods for inhibiting phosphate transport
ES2749433T3 (es) 2014-06-23 2020-03-20 Celgene Corp Apremilast para el tratamiento de una enfermedad hepática o una anomalía de la función hepática
CN106333953A (zh) * 2015-07-08 2017-01-18 珠海津之敦医药科技有限公司 尤克那非新用途
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
MX2019008171A (es) 2017-01-09 2020-02-05 Ardelyx Inc Inhibidores del antiporte mediado por nhe.
UA126283C2 (uk) 2017-01-09 2022-09-14 Арделікс, Інк. Сполуки, придатні для лікування розладів шлунково-кишкового тракту
US20220143148A1 (en) 2019-03-14 2022-05-12 The Broad Institute, Inc. Compositions and methods for modulating cgrp signaling to regulate intestinal innate lymphoid cells

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3405181A1 (de) * 1984-02-10 1985-08-22 Schering AG, 1000 Berlin und 4709 Bergkamen Neue carbacycline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
JPH01153634A (ja) * 1987-12-10 1989-06-15 Kyorin Pharmaceut Co Ltd 吸入剤
IT1239281B (it) * 1989-10-27 1993-10-19 Indena Spa Composizioni per la riduzione dei depositi di grasso superfluo a base di principi attivi di origine vegetale ad attivita' agonista dell'adenilato ciclasi o/e ad attivita' antifosfodiesterasica
EP0504112A3 (en) * 1991-03-14 1993-04-21 Ciba-Geigy Ag Pharmaceutical aerosol formulations
US6013827A (en) * 1994-03-11 2000-01-11 Smithkline Beecham Corporation Compounds
US5602110A (en) 1994-08-31 1997-02-11 Case Western Reserve University Method and composition for treating cystic fibrosis

Also Published As

Publication number Publication date
ATE386531T1 (de) 2008-03-15
DK0975347T3 (da) 2008-06-16
EP0975347B1 (de) 2008-02-20
WO1998037894A1 (de) 1998-09-03
JP2009073853A (ja) 2009-04-09
SI0975347T1 (sl) 2008-08-31
US6333354B1 (en) 2001-12-25
PT975347E (pt) 2008-05-23
EP0975347A1 (de) 2000-02-02
DE59814173D1 (de) 2008-04-03
ES2302350T3 (es) 2008-07-01
AU6823098A (en) 1998-09-18
JP2001513097A (ja) 2001-08-28

Similar Documents

Publication Publication Date Title
CY2607B2 (el) Συνεργιστικος συνδυασμος αναστολεων pde και αγωνιστων αδενυλικης κυκλασης ή αγωνιστων γουανυλικης κυκλασης
CY1111872T1 (el) Συνθεσεις υποτασικου λιπιδιου (προσταγλανδινης) και τιμολολης - σχετικες μεθοδοι χρησης
CY1105299T1 (el) Χρηση των επιλεκτικων αγωνιστων του υποδοχεα 4 (ep4) προσταγλανδινης (pge2) για τη θepαπεια της οξειας και χρονιας νεφρικης ανεπαρκειας
TR200201505T2 (tr) Terapötik maddeler olarak pirazolopirimidinler
EA200100411A1 (ru) Замещенные 3-цианохинолины в качестве ингибиторов протеинтирозинкиназ
BR0116452A (pt) Composto, composição farmacêutica, uso de um composto
TR200001218T2 (tr) İkameli karboksamidotiazoller, bunların üretimi ve bunları içeren farmasötik bileşimler.
DE60033316D1 (de) Tricyclische proteinkinasehemmer
FI954944A0 (fi) Indolijohdannaisia 5-HT1-kaltaisina agonisteina käytettäväksi migreenin hoitoon
ES2189968T3 (es) Amidinofenil-pirrolidinas,-pirrolinas,e -isoxazolidinas y derivadOS DE LOS MISMOS.
YU49101A (sh) Karboksiaril supstituisani difenil karbamidi kao inhibitori raf kinaze
EA200300248A1 (ru) Бициклопиразолы, активные в качестве ингибиторов киназы, способ их получения и включающие их фармацевтические композиции
EA200100412A1 (ru) Замещенные 3-цианохинолины в качестве ингибиторов протеинтирозинкиназ
BR9811099A (pt) Inibidores de urocinase
PT1305286E (pt) Ciclopentanoindoles composicoes que contem os referidos compostos e metodos de tratamento
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
CO5180581A1 (es) Compuestos para el tratamiento de la isquemia ciones farmaceuticas que los contienen para el tratamiento de la isquemia
CY1107383T1 (el) Αναστολεις της φωσφολιπασης α2 του κυτοπλασμικου διαλυματος
TR200200068T2 (tr) Nematisital triflüorobütenler
CY1105247T1 (el) Υποκατεστημενα παραγωγα c- κυκλοεξυλομεθυλαμινης
ES2162231T3 (es) Nuevos derivados de n-(arilsulfonil)aminoacidos que tienen afinidad con los receptores de bradicinina.
DE69840603D1 (de) Alpha-ketoamidhaltige multikatalytische protease inhibitoren
DE60019586D1 (de) Myostatin genpromoter und inhibierung dessen aktivierung
DE60230127D1 (de) Inhibitoren von integrin alpha-v-beta-6
PA8508301A1 (es) Inhibidores de la proteina c del procolageno